Hypertension is the number one reason for visits to a physician, accounting for roughly one in 10 visits. Despite extensive expenditures on the disease, only 20% of patients are well controlled. This longitudinal patient review (LPR) analysis was performed as an initial step in modeling the impact of unsuccessful outcomes in patients whose initial treatment was either an angiotensin converting enzyme inhibitor (ACEI) or a calcium channel blocker (CCB) as first-line pharmacologic therapy. In addition, the cost impact of these changes was measured pre-and post-modification in terms of pharmacy costs per member per month (PMPM).
have the disease. 1 The financial burden of the disease is staggering. The costs to society in 1997 are estimated to have been $30 billion, of which $21.8 billion are due to direct costs such as hospitalizations and physician visits.' Antihypertensive drugs (ADs) account for nearly one-third of the total direct costs ($7 billion).' Despite the resources expended on hypertension, less than 25% of patients are well controlled. 1 Because of the high cost of treating hypertension and the poor results, the health care community is rigorously debating the impact of unsuccessful outcomes in these patients. Health care providers are concerned not only about long-term costs but also about continual costs that are incurred from the time of diagnosis. In order to evaluate this issue as well as measure the impact of disease management programs on these costs, baseline and impact assessment systems need to be designed and implemented in the managed care setting. A critical aspect of these needed systems is the development of sound economic models of hypertension treatment in naturalistic settings.
The Clinical and Economic Implications of Drug Utilization Patterns in the Treatment of Hypertension with ACE Inhibitors and Calcium Channel Blockers in a Managed Care Setting A useful initial step in this model-building process is the retrospective evaluation of claims data. Because pharmacy claims are more complicated and generally more reliable than other medical claims, the LPR process is being used as the initial technique for this analysis. The purpose of this LPR was to provide AD utilization and cost analysis data that are useful for designing a prospective effectiveness and costimpact protocol for use in managed care and disease management programs, as recommended by prior investigators' Specifically, the authors are interested in determining: 1) the patterns of AD therapy modifications after the initiation of either an angiotensin converting enzyme inhibitor (ACEI) or a calcium èhannel blocker (CCB) for first-line pharmacological therapy, and 2) the potential costs of each of these choices. The data derived from pharmacy claims were utilized to describe modification patterns after the initiation of AD therapy The types of modifications suggest the categorization of the reasons for initial AD failure and can lead to suggestions cfor improving treatment protocols or better patient outcomes, or for targeting potential areas for cost savings. An estimate as to the frequency of these events is necessary in the hypertension economic modeling process. ACEI and CCB were chosen for analysis for three reasons:
... their popularity among prescribers;
... the high drug costs associated with their use as compared to other classes of AD; and ... the new combination ACEl/CCB products entering the AD market.
Additionally, while their efficacy and safety data are compelling, little is known about the effectiveness of these products when utilized in a naturalistic environment. The authors hypothesized that there are incremental costs of ADs for patients not achieving satisfactory outcomes and that these increases occur within months, rather than years. For the purpose of interpretation of these data, satisfactory outcomes are defined as a reduction in blood pressure to target levels, with tolerable adverse events.
STUDY DESIGN/METHODOLOGY
A separate analysis and review of drug utilization was conducted across six managed care organizations (MCOs) throughout the United States. The data collected represent staff-, group-, independent practice association (IPA)-, network-, and mixed-model HMOs. Participants included patients who began treatment for hypertension with an ACEl or a CCB therapy during 1993 and continued on any antihypertensive therapy through December 31, 1994. Patients were identified as "first starts" on an ACEI or a CCB if they began such treatment in 1993. In order to determine first starts, a retrospective analysis was performed, in which the MCO's medications days supply data were collected from plans on all of their antihypertensive patients. In each plan, the days supply for medication was either a 30or 60-day supply The days supply plus 30 days was the time frame observed retrospectively to determine whether a patient was a first start on an AD or a new prescription was being filled for existing therapy For example, if a plan's days supply was for 30 days, the data weré examined for a period of 60 days, (days supply plus 30 days) prior to the time when the new prescription was filled.
If a patient had no record of receiving AD within that 60-day period, the patient was assumed to be a first start. Patients with 80% or greater compliance using medication pos-session ratio (MPR) with AD therapy were included in the analysis. Any change in AD therapy over the 12-month study period was considered a modification. Each modification in AD therapy was classified into one of the following categories:
... Increased Doseany adjustment in dose resulting in an increase in the total daily dose. 
... Decreased Dose

RESULTS
Frequency of Modifications
A total of 1,932 patients started antihypertensive therapy with an ACE I or CCB in 1993 and met the other inclusion! exclusion criteria. Of these, 936 (48%) initiated therapy with an ACE!, and 996 (52%) initiated therapy with a CCB. During the subsequent 12 months, 44% of these patients required at least one modification in drug therapy (41% and 46% for ACE! and CCB, respectively).
There were 1,308 modifications made during the 12 months following initiation of drug therapy-580 and 728 for the ACE I and CCB groups, respectively The modification rate per 1,000 patients started on an AD drug was 620 (580 per 936 patients) and 731 (728 per 996 patients) for the ACEI and the CCB groups, respectively There were up to six modifications made during the 12-month follow-up in each group.
Type of Modification
The frequency of each type of first modification per group is outlined in Table 1 . Of patients requiring a modification, the most common first modification for the ACEI was an Increased Dose (40%), followed by Switched Class (27%) and Added Drug (New Clas~ (21 %). For CCBs the most common first modification was Added Drug (New Class) (25%), followed closely by Increased Dose (23%) and Switched Class (20%). Table 1 shows the distribution of the first two modifications by type of modification. There was a difference in ranking of the type of modification between the first and second modifications. While an Increased Dose was the most common change for first modification in the ACEI group (40%), the preferred second modification was Switched Class (37%). In the CCB group, the ranking for the second modification was similar to the first modification: Switched Class (28% versus 20%), Increased Dose (27% versus 23%), and Added Drug (New Class) (23% versus 25%). Further stratification of subsequent modifications resulted in numbers too small to draw conclusions from. The most common drug added to the AD in the Added Drug (New Class) category was from the other class (i.e., a CCB added to an ACE! or vice versa) as shown in Table 2 . This oécurred in 61 % of additions to the 
Timing of Modification
The median time until the first modification in antihypertensive therapy was 81 and 87 days for the ACEl and CCB groups, respectively ( Table 3 ). The ranges in the medians were 30-193 days for the ACEI group and 30-141 for the CCB group, depending on the type of modification made. those patients for whom the first modification was the addi-. tion of a drug had the lowest median time to change for both groups. Excluding those categories with an ndO, the highest median time for the ACEI group was for those patients switching class, whereas the highest median time for the CCB group was for those patients switching formulation. The aggregate modifications over the first 12 months of therapy for all modification types are displayed in Table 5 .
Over 50% of all modifications were done by the third month of therapy for those patients started on an ACEI or a CCB.
First-Year Acquisition Cost (FAC)
The first-year acquisition costs (FACs) for patients with no modifications were $322 and $427 for the ACE I and CCB groups, respectively. The FAC increased as the number of modifications increased. Table 4 illustrates the increase of annual costs and the number of prescription refills as modifications were made. The range was $391-$880 for the ACEI group and $496-$861 for the CCB group for one to six modifications. The highest costs were associated with patients having the highest number of modifications.
Excluding those categories with an n<30, Increased Dose resulted in the lowest FAC for the ACEI group ($357), while Switched Class was the lowest in the CCB group ($384), as seen in Table 3 . In all cases, patients requiring modification in AD therapy had an increase in AD costs. The one exception was those requiring the Switched Class modification in the CCB group in which the FAC declined versus those with no modification ($384 versus $427). The highest FAC occurred in the modification type Added Drug (New Class), $670 and $733 for the ACE! and CCB groups, respectively. As stated earlier, the most common addition to an ACE I was a CCB and the most common addition to a CCB was an ACE!. As expected, these groups had the highest FAC of any group ($809 and $806 for the ACEI/CCB and CCB/ACEI groups, respectively). Of note, the addition of an alpha blocker to a CCB resulted in the highest acquisition cost, but the number of patients in this category (7) was too small for the results to be reliable.
Costs Per Member Per Month
The costs per member per month (PMPM) were evaluated both pre-and post-modification (see Table 6 ). The highest In the present study, as the number of modifications increased, the FAC increased. Additionally, the number of primary care physician (PCP) visits needed to care for these patients is likely to be higher than for those patients requiring no modification in their regimen, consequently increasing associated medical costs as well. This, however, must be confirmed using integrated pharmacy and medical claims data.
Increasing the dose of the AD is considered the most logical next step for these patients, especially for those drugs having a strong dose-response relationship (e.g., the calcium channel blockers). Clinically, one would be anticipate that the better the dose-response relationship the more likely that increasing the dose would achieve satisfactory outcome, and the less likely the need for further titration in therapy. In this analysis, increasing the dose was the most common initial modification in the ACEI group and the second most common in the CCB group. A recent survey of treatment trends in hypertension from pharmacy directors in 29 managed care plans revealed interesting results4 They indicated that increasing the dose of either an ACE! or CCB was the most common modification to therapy. They estini.ated that 27% and 23% of patients taking ACE! or CCB, respectively, would increase their dose in the first 12 months of therapy.
These percentages are significantly higher that those found in the current analysis (16% and 11 %, respectively). In this survey, the respondents indicated that of those patients started on an ACEI, 18% would switch class, 11 % would switch to another ACEI, and 11 % would add a CCB. For those patients starting on a CCB, after increasing the dose the next most common modifications were adding a diuretic (15%), switching to another CCB (13%), and adding an ACE! (5%). Again, these findings were significantly different from those found in our analysis. The reason for these differences is not known. However, since this was a survey and not an actual claims analysis, comparing thes~ findings to ours is difficult. Considering that almost half of these patients required further modification in therapy, thus increasing the need for physician visits, those patients whose initial st(~p was to increase dose likely had lower total medical costs. Because noncompliant patients were excluded from the study, however, these results should be interpreted with caution. The impact that the inclusion of these data would have had on the final numbers is unknown. Overall, Switched Class was the second most frequent first modification type and, as mentioned earlier, nearly 50% of The therapeutic rationale for switching a drug within the same class, especially in the case of the ACEIs, is limited. While this occurred in very few patients in the ACEI group, nearly 5% of the patients who started on a CCB .switched within the class. Because of the differing physiologic effect and adverse event profile of drugs within this class, specifically when considering the dihydropyridines versus the nondihydropyridines, it seems a logical alternative for those with inadequate initial response to therapy As with patients in the Switched Class category, a large percentage of these patients required further modification to their regimen. The FACs for patients in this category were relatively low, especially in the CCB group.
Further breakdown of the modification types by the need for subsequent modification is shown in
Switching AD is considered in patients experiencing
Added Drug (New Class) was the third most common modification type overall. Much attention has been placed recently on the use of combination therapy, specifically the combination of drugs resulting in a synergistic effect on blood pressure. This often allows the use of lower doses of both products to achieve the same, if not better, blood pressure response and decrease the incidence of adverse events. In this analysis, the most common addition to an ACEI was a CCB and the most common addition to a CCB was an ACEL The rationale for this combination is strong, as evidenced by the large number of fixed-dose combination products currently on The Clinical and Economic Implications of Drug Utilization Patterns in the Treatment of Hypertension with ACE Inhibitors and Calcium Channel Blockers in a Managed Care Setting the market or in clinical development. As one would expect, the use of this combination resulted in the highest FAC among all categories. This would strengthen the case further for the fixed-dose combination ACEVCCB products, since the cost of the fixed-dose products is less than many of the drugs in the CCB category alone.
There are certainly weaknesses to these assumptions.
Without close examination of the medical record, blood pressure values cannot be determined to assure that the patient is at target. While it is more likely that patients in the no-modification group were well controlled, it is obviously not a certainty. Additionally, target blood pressure is defined by the PCP and is not necessarily the same as those set by national committees (i.e., <140/90 mm Hg).3
CONCLUSION
This LPR analysis strongly suggests that unsatisfactory outcomes in the management of hypertensive patients, defined as an increase in the number of AD modifications, lead to an increase in health care costs. While these data offer insight into the therapeutic process and decision making of the prescriber, additional work needs to be done. Incorporating additional outcomes data, such as clinical results and level of blood pressure control achieved with each modification type and frequency, is a needed dimension for this model building. A complete economic model also should take into account the additional direct costs of any increased ambulatory services, such as diagnostic services, as well as related hospitalizations.
Note also that the inclusion of data from noncompliant patients would potentially have an impact on the conclusions of this study, the most obvious being the modification rate. The modification rate would likely increase, since noncompliance typically leads to an unsuccessful outcome-namely not reaching target blood pressure levels.
The results from this LPR analysis do offer a strong base on which to further develop a useful economic model for hypertension therapies in the office setting. Relating the clinical explanations of therapeutic failure to the economic results as shown in the pharmacy claims data points to potential cost savings in formulary design and to improved patient outcomes. The results found here suggest that increasing the dose of an ACE! or CCB or moving the patient more quickly to combination therapies are logical first steps and have an acceptable rate of subsequent modification. These results seem to support the recently published guidelines for the management of hypertension from the Joint National Committee,S The use of combination therapy is even more attractive when considering that fixed combinations of ACE Is and CCBs are often less expensive than single-drug products. Other options such as changing the formulation of a product dosed less frequently to increase patient compliance also are valuable alternatives, In this analysis, switching the class of ADs seemed to be the least successful alternative, at least in terms of requiring future modifications to AD therapy As suggested by these data, optimizing the use of medications in the managed care setting by reducing the number of therapeutic modifications necessary to achieve appropriate blood pressure control in the patient is possible. The resulting cost savings due to reduced direct medical costs associated with these modifications and the better outcome due to reaching patient goals more quickly are both desirable in the managed care setting. ...
